Full metadata record
DC FieldValueLanguage
dc.creatorRaquel-
dc.creatorFresquet, V. (Vicente)-
dc.creatorRoman-Gomez, J. (José)-
dc.creatorBobadilla, M. (Míriam)-
dc.creatorRobles, E.F. (Eloy Francisco)-
dc.creatorAltobelli, G.G. (Giovanna G.)-
dc.creatorCalasanz-Abinzano, M.J. (Maria Jose)-
dc.creatorSmeland, E.B. (Erlend B.)-
dc.creatorAznar, M.A. (María Ángela)-
dc.creatorAgirre-Ena, X. (Xabier)-
dc.creatorMartin-Palanco, V. (Vanesa)-
dc.creatorProsper-Cardoso, F. (Felipe)-
dc.creatorLossos, I.S. (Izidore S.)-
dc.creatorMartinez-Climent, J.A. (José Ángel)-
dc.date.accessioned2012-08-09T11:55:49Z-
dc.date.available2012-08-09T11:55:49Z-
dc.date.issued2011-
dc.identifier.citationMalumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, et al. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Haematologica 2011 Jul;96(7):980-986.es_ES
dc.identifier.issn1592-8721-
dc.identifier.urihttps://hdl.handle.net/10171/23046-
dc.description.abstractBACKGROUND: LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts better clinical outcome. The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored. DESIGN AND METHODS: We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia patient samples with cytogenetic data (144 of them also with survival and immunophenotypical data) and in normal hematopoietic and lymphoid cells. RESULTS: B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells, displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature subtypes. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid karyotype. Clinically, high LMO2 expression correlated with better overall survival in adult patients (5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constituted a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043). CONCLUSIONS: Our data indicate that LMO2 expression depends on the molecular features and the differentiation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2 expression in adult patients with a normal karyotype, a group which lacks molecular prognostic factors, could be of clinical relevance.es_ES
dc.language.isoenges_ES
dc.publisherFerrata Storti Foundationes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAcute leukemiaes_ES
dc.subjectB lymphocyteses_ES
dc.subjectGene expressiones_ES
dc.subjectPrognostic factores_ES
dc.titleLMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcomees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://www.haematologica.org/content/96/7/980es_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES

Files in This Item:
Thumbnail
File
Haematol2011_96_7_980.pdf
Description
Size
511.32 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.